The Video Journal of Hematological Oncology (VJHemOnc) is pleased to share the success of the PROMISE study by the Dana-Faber Cancer Institute, Boston, MA.
The PROMISE study (NCT03689595) is a national screening study from the Dana-Farber Cancer Institute led by Dr Irene Ghobrial and funded by Stand Up To Cancer. The goal of the PROMISE study is to establish the first screen-detected cohort of patients with multiple myeloma precursor conditions in order to identify novel regulators of disease progression and therapeutic options. The PROMISE Study will also help to define the prevalence of MGUS/SMM in at-risk populations.
“This is very important, we screen for other cancers; mammography for breast cancer, colonoscopy for colon cancer. Yet we don’t do just one blood test to see if patients have a blood cancer or not, and this will change with the PROMISE study.”
The PROMISE Study has the following eligibility requirements:
✔ Participants must be between the ages of 40 and 75,
✔ Have a first degree relative with MM or a precursor condition to MM
✔ Self-identify as being of African descent, and not currently under treatment for MM or a precursor condition.
An individual who qualifies for the PROMISE study enrolls, consents, and completes all steps of the study online at: